MA-ABIOMED
Results of a three-year, investigator-led study of all Impella-supported patients treated at 109 hospitals in Japan (n=1,344) show 30-day survival rates of 81% for AMI cardiogenic shock (AMICS) patients. The study is an update to a 2020 interim analysis and was presented at the 2022 Transcatheter Cardiovascular Therapeutics (TCT) conference taking place in Boston.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220919005279/en/
Caption: The investigator-led Inova, NCSI and J-PVAD studies all demonstrate an improvement from the historical AMI cardiogenic shock survival rate of approximately 50% when patients are treated with best practices including Impella. (Graphic: Business Wire)
The analysis examined 293 consecutive Impella-supported AMICS patients in the J-PVAD Registry, a registry conducted by 10 Japanese professional societies, including the Japanese Circulation Society (JCS). Results demonstrated 81% survival at 30 days. Historical cardiogenic shock survival rates without Impella are approximately 50%.
“The results of this study demonstrate that when Impella is used and best practices are followed, it is possible to achieve heart recovery and greater than 80% survival rates for patients with AMI cardiogenic shock,” said lead investigator Junya Ako, MD, an interventional cardiologist and chair of the department of cardiovascular medicine at Kitasato University Hospital in Kanagawa.
These results are consistent with other published investigator-led studies, such as the National Cardiogenic Shock Initiative Study (NCSI) and the Inova study by Tehrani et al., that have demonstrated significant increases in survival with the use of Impella and best practices such as placing Impella prior to percutaneous coronary intervention (PCI) (see figure 1).
J-PVAD data is independently monitored and shared with the Japan Pharmaceuticals and Medical Devices Agency (PMDA).
ABOUT IMPELLA HEART PUMPS
Impella 2.5, Impella CP®, Impella CP with SmartAssist, Impella 5.0®, Impella LD®, and Impella 5.5® with SmartAssist® are U.S. FDA approved to treat heart attack or cardiomyopathy patients in cardiogenic shock and have the unique ability to enable native heart recovery, allowing patients to return home with their own heart.
ABOUT ABIOMED
Based in Danvers, Massachusetts, USA, Abiomed (ABMD), is a leading provider of medical technology that provides circulatory support and oxygenation. Our products are designed to enable the heart to rest by improving blood flow and/or provide sufficient oxygenation to those in respiratory failure. For additional information, please visit: http://www.abiomed.com.
FORWARD-LOOKING STATEMENTS
Any forward-looking statements are subject to risks and uncertainties such as those described in Abiomed's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220919005279/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Golub Capital Continues Strong Track Record of Consistent Results in 20258.1.2026 16:00:00 CET | Press release
Another Year of “Good Boring” through SpecializationClosed $25+ Billion in Financing Commitments in 2025Raised a Firm Record $20.5 Billion of New Investment CapitalLaunched GP-Led Secondaries Strategy Golub Capital delivered another year of “good boring,” consistent results for its stakeholders in 2025, aided by its commitment to specialization. “We have long believed that specialization is a key source of competitive advantage for Golub Capital,” said David Golub, President of the Firm. “The past year validated this. Our deep relationships, scale and expertise enabled us to continue delivering strong results for investors, sponsors, portfolio companies and our team despite a muted M&A environment and high levels of credit stress across the private equity ecosystem. We are grateful for our clients’ trust and remain committed to building long-term, win-win partnerships that endure through market cycles.” 2025 Highlights, based on preliminary results:1 Delivering strong credit performanc
Xsolla Kicks Off Two Weeks of Industry Programming, Community Events, and Expanding Support for Global Developers Across the UK at the Industry’s Biggest Winter Event8.1.2026 16:00:00 CET | Press release
Coordinated Activations in the UK Underscore Xsolla’s Ongoing Commitment to Building All The Things for the Video Community in Europe Xsolla, a global video game commerce company that helps developers launch, grow, and monetize their games, today announces a comprehensive program of events and activations across the United Kingdom taking place from January 10 to 22, 2026. This coordinated programming schedule reflects Xsolla’s continued investment in the UK and European games ecosystem. Capitalizing on a pivotal moment in the global games calendar, Xsolla is bringing developers, partners, and creators together through partnerships, live events, thought leadership, and community building. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260108943976/en/ (Graphic: Xsolla) “Pocket Gamer Connects London brings together one of the most diverse and forward-thinking communities in the mobile global games industry,” said Berkley Egene
AMRA Medical Introduces AMRA® BCP Scan in the Netherlands Through a Strategic Partnership with Prescan, a National Preventative Health Leader8.1.2026 15:31:00 CET | Press release
AMRA Medical, the global leader in MRI-based fat distribution and muscle composition analytics, alongside Dutch preventative healthcare leader Prescan, are pleased to announce the official launch of our cutting-edge AMRA® BCP Scan service, powered by AMRA® Profiler (CE, NB 2862), in the Netherlands. The launch, which marks BCP Scan’s third new market entry of 2025 (Sweden & Germany), expands the availability of our service within the EU into the Netherlands through an exclusive partnership with Prescan, an independent health & wellness clinic in Baarn which specializes in preventive health screenings and care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260108381985/en/ AMRA® BCP Scan available at Prescan AMRA’s CEO, Olof Dahlqvist Leinhard, stated, “This is another important step in bringing our mission of driving scientific breakthroughs into the clinic by enabling deeper understanding of health and disease through MRI-
Nexo Unveils Zero-interest Credit with 0% APR and No Fees8.1.2026 15:00:00 CET | Press release
A new, zero-cost way to unlock liquidity without selling your crypto or facing premature liquidation. Zero-interest Credit offers a clear repayment path from day one, with built-in downside protection for added confidence. Nexo, the premier digital assets wealth platform, today announced the launch of Zero-interest Credit (ZiC), now joining the Nexo Credit Line as a flagship borrowing solution. ZiC enables Bitcoin and Ethereum holders to access liquidity at 0% interest through a fixed-duration term, free from the risk of premature forced liquidation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260108785934/en/ Zero-interest Credit by Nexo Previously available through Nexo’s Private and OTC services, structured zero-interest borrowing has been used by Nexo’s private channels and is now broadly available through Zero-interest Credit. In 2025, it has enabled access to more than $140 million in liquidity. A broad solution for
ITRS Acquires IP-Label to Strengthen Digital Experience Monitoring Capabilities and Expand European Presence8.1.2026 15:00:00 CET | Press release
Strategic acquisition adds 310+ enterprise customers and proven Ekara DEM platform, solidifying ITRS's position as the leading observability platform for financial services and regulated enterprises ITRS, a leading provider of real-time IT monitoring and observability solutions for financial services and regulated industries, today announced it has signed a definitive agreement to acquire IP-Label, a premier Digital Experience Monitoring (DEM) provider headquartered in France. The acquisition strengthens ITRS's DEM capabilities and significantly expands its European market presence. IP-Label serves 310+ enterprise customers across 25 countries through its AI-powered Ekara platform, which provides comprehensive synthetic transaction monitoring (STM), Real User Monitoring (RUM), and AI-driven incident triage to proactively identify and resolve performance issues before they affect customers or employees. The Ekara platform's unique capabilities include monitoring of complex web applicati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom